Efficacy and safety of the implantable, magnetic resonance imaging‐compatible StimRouter neuromodulation system in the treatment of refractory lower urinary tract symptoms in multiple sclerosis patients
European Journal of Neurology · 2024
DOI: 10.1111/ene.16146 ↗Kurz gefasst
Klinische Studie in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Rosaria Sacco und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Regional Hospital (EOC) of Lugano, Lugano, Switzerland. Hauptthemen laut MEDLINE: Lower Urinary Tract Symptoms, Multiple Sclerosis, Urinary Bladder, Neurogenic, Urinary Bladder, Overactive. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Advisory Board of Ente Ospedaliero Cantonale (EOC), the Swiss Multiple Sclerosis Society.
Abstract (Originalsprache)
Background and purpose Lower urinary tract symptoms (LUTS) significantly affect quality of life (QoL) of multiple sclerosis (MS) patients, and pharmacotherapy has limited efficacy. We investigated efficacy and safety of the implantable StimRouter neuromodulation system for treating refractory LUTS in MS.
Methods
This prospective, single‐center, clinical trial was conducted at the Multiple Sclerosis Center of Lugano, Switzerland, involving MS patients treated with self‐administered percutaneous tibial nerve stimulation delivered by StimRouter over 24 weeks. Changes in video‐urodynamic parameters as well as LUTS severity were measured by Overactive Bladder Questionnaire (OAB‐q), QoL using the Multiple Sclerosis Quality of Life (MSQoL‐54), and treatment satisfaction using a 1–10 visual analogue scale. Adverse events were also recorded.
Results
Of 23 MS patients recruited, six had neurogenic detrusor overactivity (NDO), five had detrusor sphincter dyssynergia (DSD), and 12 had both NDO and DSD. Of patients with NDO, median bladder volume at first uninhibited contraction significantly increased from baseline to week 24 (median = 136 mL, interquartile range [IQR] = 101–244 mL vs. 343 mL, IQR = 237–391 mL; β = 138.2, p = 0.001). No significant changes of urodynamic parameters were found in patients with DSD. OAB‐q symptom scores progressively decreased, and OAB‐q quality of life scores increased ( β = −0.50, p < 0.001 and β = 0.47, p < 0.001, respectively), whereas MSQoL‐54 scores did not significantly change ( β = 0.24, p = 0.084) in the overall population. Treatment satisfaction was overall high (median = 8, IQR = 6–9). No serious adverse events were recorded.
Conclusions
StimRouter represents a minimally invasive, magnetic resonance imaging‐compatible, self‐administered neuromodulation device leading to objective and subjective improvements of OAB symptoms and related QoL in MS patients with refractory LUTS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Regional Hospital (EOC) of Lugano, Lugano, Switzerland.
- Anestesiologia, Neurocenter of Southern Switzerland, Regional Hospital (EOC) of Lugano, Lugano, Switzerland.
- Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland.
- Urology Service, Ospedale Regionale di Bellinzona e Valli (EOC), Bellinzona, Switzerland.
- Department of Urogynaecology, Imperial College Healthcare NHS Trust, London, UK.
ORCID-Profile: Rosaria Sacco, Giulio Disanto, Claudio Gobbi, Chiara Zecca
Förderung
- Research Advisory Board of Ente Ospedaliero Cantonale (EOC)
- the Swiss Multiple Sclerosis Society
Zitieren
APA
Sacco, R., Maino, P., Koetsier, E., Disanto, G., Renard, J., Digesu, A., Gobbi, C., & Zecca, C. (2024). Efficacy and safety of the implantable, magnetic resonance imaging‐compatible StimRouter neuromodulation system in the treatment of refractory lower urinary tract symptoms in multiple sclerosis patients. European Journal of Neurology. https://doi.org/10.1111/ene.16146
Vancouver
Sacco R, Maino P, Koetsier E, Disanto G, Renard J, Digesu A, et al. Efficacy and safety of the implantable, magnetic resonance imaging‐compatible StimRouter neuromodulation system in the treatment of refractory lower urinary tract symptoms in multiple sclerosis patients. European Journal of Neurology. 2024. doi:10.1111/ene.16146
BibTeX
@article{Sacco2024,
author = {Sacco, Rosaria and Maino, Paolo and Koetsier, Eva and Disanto, Giulio and Renard, Julien and Digesu, Alex and Gobbi, Claudio and Zecca, Chiara},
title = {Efficacy and safety of the implantable, magnetic resonance imaging‐compatible StimRouter neuromodulation system in the treatment of refractory lower urinary tract symptoms in multiple sclerosis patients},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16146}
}
EUVIMED